DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key advancements in its clinical-stage therapeutic candidates. The company is making significant strides in the development of its WEE1 inhibitor, APR-1051, and ATR inhibitor, ATRN-119, alongside bolstering its team with the appointment of Dr. Philippe Pultar as a senior medical advisor.
Aprea’s Phase 1 ACESOT-1051 trial is progressing ahead of schedule, evaluating the WEE1 inhibitor APR-1051, which has shown promise in treating cancers with Cyclin E over-expression. Preliminary findings displayed no unexpected toxicities, bolstering confidence in its potential best-in-class status. Concurrently, the Phase 1/2a ABOYA-119 study is assessing ATRN-119 for patients with DDR-related gene mutations, a category of cancer with high unmet needs.
Operational enhancements include the engagement of Dr. Philippe Pultar, an experienced oncology executive, to guide the advancement of APR-1051. Dr. Pultar’s expertise, particularly in the strategy and execution of oncology programs, is expected to drive forward Aprea’s clinical objectives.
Financially, Aprea ended the quarter with cash reserves of $26.2 million, ensuring sufficient runway for at least the next twelve months. The company reported a net loss of $3.8 million, compared to a $3.2 million loss in the same quarter last year, reflecting increased investments in clinical development.
Research and development expenses rose to $2.8 million, driven by ongoing trials and personnel investments, while general and administrative costs saw a slight decline to $1.6 million, attributed to reduced insurance expenses.
Aprea’s continued focus on advancing its pipeline underscores its commitment to developing transformative cancer therapies, with expectations of releasing further trial data in 2025.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.